{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:16:55Z","timestamp":1787170615810,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008966","name":"Soci\u00e9t\u00e9 Francophone du Diab\u00e8te","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008966","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Heart failure (HF) is a growing complication and one of the leading causes of mortality in people living with type 2 diabetes (T2D). Among the possible causes, the excess of red meat and the insufficiency of vegetables consumption are suspected. Such an alimentation is associated with nutritional biomarkers, including trimethylamine\n                      <jats:italic>N<\/jats:italic>\n                      -oxide (TMAO) and its precursors. Here, we aimed to study these biomarkers as potential prognostic factors for HF in patients with T2D.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used the SURDIAGENE (SURvival DIAbetes and GENEtics) study, a large, prospective, monocentric cohort study including 1468 patients with T2D between 2001 and 2012. TMAO and its precursors (trimethylamine [TMA], betaine, choline, and carnitine) as well as thio-amino-acids (cysteine, homocysteine and methionine) were measured by liquid chromatography-tandem mass spectrometry. The main outcome was HF requiring Hospitalization (HFrH) defined as the first occurrence of acute HF leading to hospitalization and\/or death, established by an adjudication committee, based on hospital records until 31st December 2015. The secondary outcomes were the composite event HFrH and\/or cardiovascular death and all-cause death. The association between the biomarkers and the outcomes was studied using cause-specific hazard-models, adjusted for age, sex, history of coronary artery disease, NT-proBNP, CKD-EPI-derived eGFR and the urine albumin\/creatinine ratio. Hazard-ratios (HR) are expressed for one standard deviation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The data of interest were available for 1349\/1468 of SURDIAGENE participants (91.9%), including 569 (42.2%) women, with a mean age of 64.3\u2009\u00b1\u200910.7\u00a0years and a median follow-up of 7.3\u00a0years [25th\u201375th percentile, 4.7\u201310.8]. HFrH was reported in 209 patients (15.5%), HFrH and\/or cardiovascular death in 341 (25.3%) and all-cause death in 447 (33.1%). In unadjusted hazard-models, carnitine (HR\u2009=\u20091.20, 95% CI [1.05; 1.37]), betaine (HR\u2009=\u20091.34, [1.20; 1.50]), choline (HR\u2009=\u20091.35, [1.20; 1.52]), TMAO (HR\u2009=\u20091.32, [1.16; 1.50]), cysteine (HR\u2009=\u20091.38, [1.21; 1.58]) and homocysteine (HR\u2009=\u20091.28, [1.17; 1.39]) were associated with HFrH, but not TMA and methionine. In the fully adjusted models, none of these associations was significant, neither for HFrH nor for HFrH and\/or CV death, when homocysteine only was positively associated with all-cause death (HR\u2009=\u20091.16, [1.06; 1.27]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TMAO and its precursors do not appear to be substantial prognosis factors for HFrH, beyond usual cardiac- and kidney-related risk factors, whereas homocysteine is an independent risk factor for all-cause death in patients with T2D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-022-01505-9","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T14:03:50Z","timestamp":1654783430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Nutritional biomarkers and heart failure requiring hospitalization in patients with type 2 diabetes: the SURDIAGENE cohort"],"prefix":"10.1186","volume":"21","author":[{"given":"Matthieu","family":"Wargny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika\u00ebl","family":"Croyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Ragot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Gand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jacobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-No\u00ebl","family":"Trochu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Prieur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Le May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Goronflot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Jean","family":"Saulnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Hadjadj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the SURDIAGENE study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Marechaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Javaugue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hulin-Delmotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Llatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Ducrocq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rigalleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Pucheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Montaigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Halimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gatault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Sosner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnabas","family":"Gellen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"1505_CR1","unstructured":"IDF Atlas 9th edition and other resources [Internet]. https:\/\/diabetesatlas.org\/en\/resources\/. Accessed 30 Apr 2021."},{"key":"1505_CR2","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Eliasson B, Svensson A-M, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407\u201318.","journal-title":"N Engl J Med"},{"key":"1505_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, Sattar N, Eliasson B, Svensson A-M, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633\u201344.","journal-title":"N Engl J Med"},{"key":"1505_CR4","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1007\/s00125-019-4926-x","volume":"62","author":"T Ohkuma","year":"2019","unstructured":"Ohkuma T, Komorita Y, Peters SAE, Woodward M. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia. 2019;62:1550\u201360.","journal-title":"Diabetologia"},{"key":"1505_CR5","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1056\/NEJMoa2007123","volume":"384","author":"DJA Jenkins","year":"2021","unstructured":"Jenkins DJA, Dehghan M, Mente A, Bangdiwala SI, Rangarajan S, Srichaikul K, et al. Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality. N Engl J Med. 2021;384:1312\u201322.","journal-title":"N Engl J Med"},{"key":"1505_CR6","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891\u2013975.","DOI":"10.1002\/ejhf.592"},{"key":"1505_CR7","doi-asserted-by":"crossref","unstructured":"Croyal M, Saulnier P-J, Aguesse A, Gand E, Ragot S, Roussel R, et al. Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2020;105.","DOI":"10.1210\/clinem\/dgaa188"},{"key":"1505_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(18)31788-4","volume":"393","author":"W Willett","year":"2019","unstructured":"Willett W, Rockstr\u00f6m J, Loken B, Springmann M, Lang T, Vermeulen S, et al. Food in the Anthropocene: the EAT-Lancet Commission on healthy diets from sustainable food systems. Lancet Lond Engl. 2019;393:447\u201392.","journal-title":"Lancet Lond Engl"},{"key":"1505_CR9","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.2337\/dc07-2079","volume":"31","author":"S Hadjadj","year":"2008","unstructured":"Hadjadj S, Fumeron F, Roussel R, Saulnier P-J, Gallois Y, Ankotche A, et al. Prognostic value of the insertion\/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies. Diabetes Care. 2008;31:1847\u201352.","journal-title":"Diabetes Care"},{"key":"1505_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312.","journal-title":"Ann Intern Med"},{"key":"1505_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","volume":"133","author":"PC Austin","year":"2016","unstructured":"Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133:601\u20139.","journal-title":"Circulation"},{"key":"1505_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"1505_CR13","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1016\/j.csda.2005.07.015","volume":"50","author":"W Sauerbrei","year":"2006","unstructured":"Sauerbrei W, Meier-Hirmer C, Benner A, Royston P. Multivariable regression model building by using fractional polynomials: description of SAS, STATA and R programs. Comput Stat Data Anal. 2006;50:3464\u201385.","journal-title":"Comput Stat Data Anal"},{"key":"1505_CR14","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2020. https:\/\/www.R-project.org\/"},{"key":"1505_CR15","unstructured":"Gray B. cmprsk: Subdistribution Analysis of Competing Risks [Internet]. 2020 [cited 2021 Jan 1].: https:\/\/CRAN.R-project.org\/package=cmprsk"},{"key":"1505_CR16","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","volume":"133","author":"CC Low Wang","year":"2016","unstructured":"Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus\u2014mechanisms, management, and clinical considerations. Circulation. 2016;133:2459\u2013502.","journal-title":"Circulation"},{"key":"1505_CR17","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1016\/j.jacc.2019.03.002","volume":"73","author":"S Verma","year":"2019","unstructured":"Verma S, Wanner C, Zwiener I, Ofstad AP, George JT, Fitchett D, et al. Influence of microvascular disease on cardiovascular events in type 2 diabetes. J Am Coll Cardiol. 2019;73:2780\u20132.","journal-title":"J Am Coll Cardiol"},{"key":"1505_CR18","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.2337\/dc18-2515","volume":"42","author":"J Tromp","year":"2019","unstructured":"Tromp J, Lim SL, Tay WT, Teng T-HK, Chandramouli C, Ouwerkerk W, et al. Microvascular disease in patients with diabetes with heart failure and reduced ejection versus preserved ejection fraction. Diabetes Care. 2019;42:1792\u20139.","journal-title":"Diabetes Care"},{"key":"1505_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2337\/dc17-0755","volume":"41","author":"PB Sandesara","year":"2018","unstructured":"Sandesara PB, O\u2019Neal WT, Kelli HM, Samman-Tahhan A, Hammadah M, Quyyumi AA, et al. The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction. Diabetes Care. 2018;41:150\u20135.","journal-title":"Diabetes Care"},{"key":"1505_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.amjmed.2020.11.007","volume":"134","author":"JP Ferreira","year":"2021","unstructured":"Ferreira JP, Sharma A, Zannad F. The future of meat: health impact assessment with randomized evidence. Am J Med. 2021;134:569\u201375.","journal-title":"Am J Med"},{"key":"1505_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1056\/NEJM200101043440101","volume":"344","author":"FM Sacks","year":"2001","unstructured":"Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3\u201310.","journal-title":"N Engl J Med"},{"key":"1505_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.nut.2012.12.018","volume":"29","author":"A Salehi-Abargouei","year":"2013","unstructured":"Salehi-Abargouei A, Maghsoudi Z, Shirani F, Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases\u2013incidence: a systematic review and meta-analysis on observational prospective studies. Nutr Burbank Los Angel Cty Calif. 2013;29:611\u20138.","journal-title":"Nutr Burbank Los Angel Cty Calif"},{"key":"1505_CR23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800389","volume":"378","author":"R Estruch","year":"2018","unstructured":"Estruch R, Ros E, Salas-Salvad\u00f3 J, Covas M-I, Corella D, Ar\u00f3s F, et al. primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018;378: e34.","journal-title":"N Engl J Med"},{"key":"1505_CR24","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMoa060900","volume":"354","author":"E Lonn","year":"2006","unstructured":"Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567\u201377.","journal-title":"N Engl J Med"},{"key":"1505_CR25","first-page":"CD006612","volume":"1","author":"AJ Mart\u00ed-Carvajal","year":"2015","unstructured":"Mart\u00ed-Carvajal AJ, Sol\u00e0 I, Lathyris D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2015;1:CD006612.","journal-title":"Cochrane Database Syst Rev"},{"key":"1505_CR26","doi-asserted-by":"publisher","first-page":"374","DOI":"10.5694\/mja2.50781","volume":"213","author":"W Li","year":"2020","unstructured":"Li W, Huang A, Zhu H, Liu X, Huang X, Huang Y, et al. Gut microbiota-derived trimethylamine N-oxide is associated with poor prognosis in patients with heart failure. Med J Aust. 2020;213:374\u20139.","journal-title":"Med J Aust"},{"key":"1505_CR27","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/joim.12328","volume":"277","author":"M Tr\u00f8seid","year":"2015","unstructured":"Tr\u00f8seid M, Ueland T, Hov JR, Svardal A, Gregersen I, Dahl CP, et al. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure. J Intern Med. 2015;277:717\u201326.","journal-title":"J Intern Med"},{"key":"1505_CR28","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1016\/j.jacc.2014.02.617","volume":"64","author":"WHW Tang","year":"2014","unstructured":"Tang WHW, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol. 2014;64:1908\u201314.","journal-title":"J Am Coll Cardiol"},{"key":"1505_CR29","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1681\/ASN.2004100846","volume":"16","author":"AN Friedman","year":"2005","unstructured":"Friedman AN, Hunsicker LG, Selhub J, Bostom AG, Collaborative Study Group. Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. J Am Soc Nephrol JASN. 2005;16:3397\u2013402.","journal-title":"J Am Soc Nephrol JASN."},{"key":"1505_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026875","volume":"100","author":"N Jin","year":"2021","unstructured":"Jin N, Huang L, Hong J, Zhao X, Chen Y, Hu J, et al. Elevated homocysteine levels in patients with heart failure: a systematic review and meta-analysis. Medicine. 2021;100: e26875.","journal-title":"Medicine"},{"issue":"Suppl 1","key":"1505_CR31","doi-asserted-by":"publisher","first-page":"320S","DOI":"10.3945\/ajcn.113.071431","volume":"100","author":"MA Mart\u00ednez-Gonz\u00e1lez","year":"2014","unstructured":"Mart\u00ednez-Gonz\u00e1lez MA, S\u00e1nchez-Tainta A, Corella D, Salas-Salvad\u00f3 J, Ros E, Ar\u00f3s F, et al. A provegetarian food pattern and reduction in total mortality in the Prevenci\u00f3n con Dieta Mediterr\u00e1nea (PREDIMED) study. Am J Clin Nutr. 2014;100(Suppl 1):320S-S328.","journal-title":"Am J Clin Nutr"},{"key":"1505_CR32","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01505-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01505-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01505-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T14:05:54Z","timestamp":1654783554000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01505-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1505"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01505-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"assertion":[{"value":"19 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The SURDIAGENE (SURvie, DIAb\u00e8te de type 2 et GENEtique) study was approved by the Poitiers University Ethics Committee. All participants gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors consent to this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest related to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}